Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Biden names U.S. monkeypox coordinators as more states cite emergencies

Published 08/02/2022, 12:08 AM
Updated 08/02/2022, 04:41 PM
© Reuters. FILE PHOTO: Test tubes labeled "Monkeypox virus positive and negative" are seen in this illustration taken May 23, 2022. REUTERS/Dado Ruvic/Illustration

WASHINGTON (Reuters) -President Joe Biden has appointed two top federal officials to coordinate his administration's response to monkeypox, the White House said on Tuesday, as more states declared emergencies to help boost vaccines and other resources to combat the virus.

The top officials from the Federal Emergency Management Agency (FEMA) and the Centers for Disease Control and Prevention (CDC) will coordinate the U.S. response across the federal government even as Biden's administration has stopped short of declaring a national emergency.

The appointments come as the United States aims to bolster vaccination efforts to slow the spread of a monkeypox outbreak that has infected more than 5,800 Americans.

"Over the coming weeks ... the administration will advance and accelerate the United States’ monkeypox response to mitigate the spread of the virus, protect individuals most at risk of contracting the virus, and care for those who have been afflicted with it," the White House said in a statement.

California and Illinois on Monday announced a state of emergency over monkeypox, following New York's declaration last week.

Robert Fenton, a FEMA regional administrator, will serve as the White House monkeypox coordinator and Demetre Daskalakis, CDC's HIV prevention chief, will serve as deputy coordinator.

The pair will coordinate Biden's response "including equitably increasing the availability of tests, vaccinations and treatments," the White House said. The administration has estimated it may need nearly $7 billion to combat the outbreak, according to the Washington Post.

Unlike when COVID-19 emerged, there are already vaccines and treatments available for monkeypox, which was first documented in Africa in the 1970s. Companies, however, must scale up production to meet rising demand.

The first U.S. case of monkeypox was confirmed in Massachusetts in May, followed by another case in California five days later.

© Reuters. FILE PHOTO: Test tubes labeled

Monkeypox, which spreads through close physical contact, causes flu-like symptoms and pus-filled skin lesions, though it is rarely fatal. It also spreads less easily than the novel coronavirus.

The World Health Organization declared monkeypox a global health emergency on July 23.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.